A PYMNTS Company

China: Signals more antitrust scrutiny for drugmakers over prices

By  |  June 30, 2016

Chinese regulators are closely examining the pricing methods of local and foreign drugmakers for any antitrust violations, according to a state-run financial newspaper, as the government conducts a wide-ranging campaign to regulate prices of medicines.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Antitrust watchdogs are looking for violations such as price manipulation among competitors or via the distribution chain, according to a report by the Securities Times, which cited a recent speech in Shanghai by Lu Yanchun, deputy head of the National Development and Reform Commission’s price supervision and anti-monopoly bureau.

    Some foreign pharmaceutical companies try to prevent generic drugs from entering the market by applying for new patents on old drugs whose original patents are close to expiration, without substantially changing the efficacy of the medicines, Lu said, according to the Securities Times.

    R&D-based Pharmaceutical Association Committee, an industry group representing foreign drugmakers did not respond to a request for comment.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.